newsfilter
← Latest News
PR Newswire·

Theseus Pharmaceuticals Announces Preclinical Data Characterizing Next-Generation Epidermal Growth Factor Receptor (EGFR) Inhibitors at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Poster presentation details lead compounds demonstrating activity against EGFR variants that are resistant to all approved EGFR inhibitors Nomination of development candidate expected in Q3 2022; IND expected in 2023 CAMBRIDGE, Mass., April 8, 2022 /